Trial · NCT04641962
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| DBT Period: Up to 52 Weeks | STARTED | DBT: Bocidelpar 30 mg | 12 | |
| DBT Period: Up to 52 Weeks | STARTED | DBT: Bocidelpar 75 mg | 11 | |
| DBT Period: Up to 52 Weeks | STARTED | Bocidelpar 30 mg or 75mg to Open Label Extension Period: Bocidelpar 30 mg | 0 | |
| DBT Period: Up to 52 Weeks | STARTED | DBT: Placebo | 11 | |
| DBT Period: Up to 52 Weeks | STARTED | Placebo to OLE Period: Bocidelpar 30 mg | 0 | |
| DBT Period: Up to 52 Weeks | COMPLETED | DBT: Bocidelpar 30 mg | 5 | |
| DBT Period: Up to 52 Weeks | COMPLETED | DBT: Bocidelpar 75 mg | 5 | |
| DBT Period: Up to 52 Weeks | COMPLETED | Bocidelpar 30 mg or 75mg to Open Label Extension Period: Bocidelpar 30 mg | 0 | |
| DBT Period: Up to 52 Weeks | COMPLETED | DBT: Placebo | 3 | |
| DBT Period: Up to 52 Weeks | COMPLETED | Placebo to OLE Period: Bocidelpar 30 mg | 0 | |
| DBT Period: Up to 52 Weeks | NOT COMPLETED | DBT: Bocidelpar 30 mg | 7 | |
| DBT Period: Up to 52 Weeks | NOT COMPLETED | DBT: Bocidelpar 75 mg | 6 | |
| DBT Period: Up to 52 Weeks | NOT COMPLETED | Bocidelpar 30 mg or 75mg to Open Label Extension Period: Bocidelpar 30 mg | 0 | |
| DBT Period: Up to 52 Weeks | NOT COMPLETED | DBT: Placebo | 8 | |
| DBT Period: Up to 52 Weeks | NOT COMPLETED | Placebo to OLE Period: Bocidelpar 30 mg | 0 | |
| OLE Treatment Period: Up to 76 Weeks | STARTED | DBT: Bocidelpar 30 mg | 0 | |
| OLE Treatment Period: Up to 76 Weeks | STARTED | DBT: Bocidelpar 75 mg | 0 | |
| OLE Treatment Period: Up to 76 Weeks | STARTED | Bocidelpar 30 mg or 75mg to Open Label Extension Period: Bocidelpar 30 mg | 10 | |
| OLE Treatment Period: Up to 76 Weeks | STARTED | DBT: Placebo | 0 | |
| OLE Treatment Period: Up to 76 Weeks | STARTED | Placebo to OLE Period: Bocidelpar 30 mg | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04641962/flow